Announcements Trials
Browse Landscape

Status

Terminated 5Withdrawn 3Unknown 3Not yet recruiting 2Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × DNA × Clear all
NCT05111067 2024-08-21

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Nova Scotia Health Authority

Completed
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT00984035 2018-09-11

Investigation of Cisplatin-Related Kidney Toxicity

University of Chicago

Completed
102 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡